Sage Therapeutics Stock News

Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sage Therapeutics (SAGE) and Biogen's (BIIB) depression candidate, zuranolone given along with antidepressants improves depressive symptoms in a phase III study. Questions remain about the durability

Sage Therapeutics (SAGE) and Biogen's (BIIB) depression candidate, zuranolone given along with antidepressants improves depressive symptoms in a phase III study. Questions remain about the durability

Sage Therapeutics Inc (SAGE) shares closed 0.3% lower than its previous 52 week low, giving the company a market cap of $2B. The stock is currently up 2.3% year-to-date, down 49.7% over the past 12 months, and down 24.5% over the past five years. This week, the Dow Jones Industrial Average fell 1.2%, and the S&P 500 fell 1.1%. Trading Activity Trading volume this week was 46.0% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -123.8% The company's stock price performance over the past 12 months lags the peer average by 63.0% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -55.6% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Sage Therapeutics Inc (SAGE) shares closed today 17.4% lower than it did at the end of yesterday. The stock is currently up 2.3% year-to-date, down 49.7% over the past 12 months, and down 24.5% over the past five years. Today, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 rose 0.1%. Trading Activity Shares traded as high as $45.61 and as low as $35.30 this week.Shares closed 59.4% below its 52-week high and 0.3% below its 52-week low.Trading volume this week was 25.4% lower than the 10-day average and 29.7% lower than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -123.8% The company's stock price performance over the past 12 months lags the peer average by 63.0% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -55.6% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

(Bloomberg) -- Former high flying biotechnology favorites Mirati Therapeutics Inc. and Sage Therapeutics Inc. have lost more than half their value from record highs, hurt by growing pessimism on new medicines as well as the higher rate environment damaging most stocks.

The late-stage trial results for the company's major depressive disorder drug aren't impressing investors today.

The late-stage trial results for the company''s major depressive disorder drug aren''t impressing investors today.

Sage Therapeutics Inc (NASDAQ: SAGE ) and Biogen Inc (NASDAQ: BIIB ) said zuranolone combined with a standard of care antidepressant met the primary goal of showing rapid and significant reduction in depressive symptoms in a late-stage study . The drug, zuranolone, also met the study''s secondary goal of showing an improvement in symptoms … Full story available on Benzinga.com

Shares of Sage Therapeutics Inc. tumbled 11.2% in premarket trading on Wednesday after Wall Street raised questions about the durability of the experimental treatment for major depressive disorder that Sage is developing with Biogen Inc. . Biogen''s stock was up 0.7% in premarket trading. The companies had announced Monday morning that zuranolone met the primary endpoint in a Phase 3 clinical trial; however, some analysts still have concerns about the commercial appeal of the drug, if it is approved by the Food and Drug Administration. The data demonstrated that there was no statistical difference between giving zuranolone with an antidepressant and an antidepressant with placebo at the 42-day mark. "Some suggestion of near-term durability would be key to broaden commercial uptake of the agent (and perhaps ensure FDA comfort with the consistency of effects across the studies)," RBC Capital Markets analyst Brian Abrahams told investors on Monday. Sage''s stock is down 48.4% over the past year, while the broader S&P 500 is up 15.2%.

(Reuters) -Sage Therapeutics Inc said on Wednesday its drug along with an antidepressant helped improve depressive symptoms after three days in a late-stage study, paving way for the drug developer to submit data for U.S. approval this year.

Sage Therapeutics said Wednesday that its experimental anti-depression pill alleviated symptoms within three days of treatment, achieving the goal of a clinical trial involving patients with major depressive disorder.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced the CORAL Study in people with major depressive disorder (MDD) met the trial objectives, demonstrating a rapid and statistically significant reduction in depressive symptoms at Day 3 and over the 2-week treatment period, achieving the primary and key secondary endpoints. This significance was demonstrated at the first measured time point, Day 3, with zuranolone 50 mg co-init

Sage Therapeutics, Inc. (SAGE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Sage Therapeutics, Inc. (SAGE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).